Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2005

View Archived Issues

Evidence suggests oxidized phospholipids may increase the risk of coronary artery disease

Genzyme reviews pipeline progress through quarter

ImaRx Therapeutics receives SBIR grant for targeted nanobubble development

CytoGenix and Aldevron collaborate on DNA vaccine technology

Lilly reports phase III results for ruboxistaurin mesilate

Phase III Flurizan trial enrolling on schedule

Imvamune protects against monkeypox in vivo

Good safety profile reported for GTI-2040 in advanced cancer

Quetiapine improves depression in patients with bipolar disorder

Phase I data on the safety profile of CTA-018 in patients with plaque psoriasis

Promising phase III data shows ISA-247 is safe and effective in plaque psoriasis

Prasugrel decreases the incidence of cardiac events in patients undergoing PCI

Oncotherapy Science and ConGenex to develop anticancer compounds

Japanese conditions for approval of Remicade relaxed

Gene therapy targeting survivin reverses PAH

Kissei launches thromboxane synthetase inhibitor Xanbon S in Japan

Diovan approved for high-risk heart attack survivors

Novel antiinfective agents reported in recent patents

New agents for cardiovascular diseases in early development

New potential cancer treatments disclosed in patent literature

Withdrawal of Infanrix HepB marketing authorization in Europe

Selective serotonin 5-HT6 antagonists improve memory formation in rats

Novel antihyperglycemic agent reduces hepatic glucose production

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...